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The combination of ﬂuorescein-containing liposomes (FCL) and magnetic resonance-guided high inten-
sity focused ultrasound (MR-HIFU)-triggered release is a promising approach for lesion demarcation
and more efﬁcient removal of non-palpable breast lesions. Exposure of FCL to ablation temperatures
(60 C) using MR-HIFU would result in palpable, stained tumors, which are more easy to identify during
surgical resection. In this study, proof-of-concept concerning ﬂuorescent FCL for MR-HIFU-triggered
release and tumor demarcation of non-palpable breast lesions is presented. Ex vivo experiments in
human blood and porcine muscle tissue showed increased label release from the liposomes, clear ﬂuores-
cence enhancement and diffusion of the released compound after heating to 60 C. Next, ﬂuorescein
release of FCL was observed after MR-HIFU-mediated mild hyperthermia (42 C) and ablation tempera-
ture (60 C) for a short period (30 s), which is in line with the clinically relevant MR-HIFU treatment
parameters. These results indicate the potential of the FCL as a tool to improve tumor demarcation in
patients by MR-HIFU-triggered release. Therefore, this method may offer a new tool for efﬁcient surgical
resection of non-palpable breast tumor lesions by enabling proper discrimination between tumor tissue
and adjacent healthy tissue.
 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
One of the main difﬁculties in surgical breast tumor resection is
to distinguish non-palpable breast lesions from healthy tissue.
Smith-Bindman et al. stated after a screening mammography study
in the UK and the US that 10–55% of the detected suspicious non-
palpable lesions were malignant [1]. These patients must undergo
intensive treatments like lumpectomy or mastectomy to ascertain
100% removal of the malignancies. Axillary lymph node dissection
and loss of breast tissue severely affects the quality of life of the pa-
tients. Hence, it is important to improve lesion demarcation to re-
duce the removal of healthy tissue. Consequently, there is a need
for a method that enables proper discrimination between tumor
tissue and adjacent healthy tissue to ensure efﬁcient complete tu-
mor removal.trecht, The Netherlands. Tel.:
erlemans).
evier OA license.Nowadays, the use of magnetic resonance imaging (MRI) as a
non-invasive diagnostic modality for characterization of suspicious
breast lesions has become an additional diagnostic tool next to
conventional techniques like mammography and ultrasound [2].
A recent clinically available non-invasive technique, that combines
MRI with thermal ablation, is magnetic resonance-guided high
intensity focused ultrasound (MR-HIFU) [3]. MR-HIFU is able to
heat tissue with pinpoint accuracy thereby ablating malignant
cells. Temperatures to be reached for this purpose are 60 C and
higher. Currently, clinical trials are performed on MR-HIFU treat-
ment of uterine ﬁbroids and prostate cancer [4,5]. Extensive pre-
clinical research has been performed to expand the possibilities
of this technique to breast tumor treatment [6,7]. Unfortunately,
100% tumor ablation cannot be guaranteed [6]. Especially for
tumors with undeﬁned margins and scattered multiple foci,
MR-HIFU-mediated tumor ablation is not suitable [8]. Therefore,
surgical resection remains important in the clinical setting.
A recent development in anti-cancer therapy is the combination
of MR-HIFU and drug-containing nanoparticles like thermosensi-
tive liposomes, which release their content upon application of a
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MR-HIFU-mediated ablation and thermosensitive liposomes has
not been explored as yet. Although treatment of the lesions with
MR-HIFU alone will result in coagulated tissue, which becomes
palpable and consequently more easy to identify, visual detection
of the malignant areas during surgery will still be difﬁcult. So, it
would be beneﬁcial to enable visual discrimination of the lesions
from healthy tissue. Margin marking of the lesions with a dye
would help to facilitate more efﬁcient lesion resection. An appro-
priate ﬂuorescent dye for this purpose is ﬂuorescein, since it is al-
ready used as a diagnostic tool in combination with ultraviolet
(UV) light in a clinical setting and can therefore be safely used in
patients [13–15]. Moreover, ﬂuorescein is a self-quenching dye,
which means that no ﬂuorescence is detected at high intraliposo-
mal concentration [16]. This has the advantage that the dye can
only be detected with UV light after it is being released from the
liposomes enabling proper discrimination of the MR-HIFU-treated
malignant tissue from the non-treated healthy tissue.
The concept of this novel approach to improve efﬁciency in le-
sion resection after the MR-HIFU-mediated ablation procedure
starts with intravenous administration of ﬂuorescein-containing
liposomes (FCL). To ensure a sufﬁcient liposome accumulation at
the tumor tissue, it is essential to include cholesterol and poly(eth-
ylene glycol) (PEG) into the liposome formulation for high stability
and long circulation, respectively, while the inclusion of a thermo-
sensitive phospholipid such as 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine (DPPC) enables MR-HIFU-mediated ﬂuorescein release
from the liposomes. By virtue of the enhanced permeability and
retention (EPR) effect, liposomes with a size of around 100 nm
are able to extravasate from the blood vessels into the tumor tissue
[17–21]. Subsequently, the high ablation temperature as applied
by MR-HIFU will trigger the FCL to release their dye, which will dif-
fuse throughout the surrounding tumor tissue, resulting in tumor
demarcation.
In this study, FCL, which are able to release their content after
exposure to MR-HIFU-mediated ablation temperatures, are devel-
oped, and proof-of-concept is provided for the proposed approach
to improve lumpectomy based on a combination of FCL and MR-
HIFU.2. Materials and methods
2.1. Materials
All chemicals and lipids were commercially available and used
as obtained. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
and 1,2-dipalmitoyl-sn-glycero-3-phospho-ethanolamine-N-
[methoxy(polyethylene glycol)-2000] (PEG2000-DSPE) were ob-
tained from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol
(>99%), glutathione (reduced, >99%); Triton X-100 and silicon diox-
ide (SiO2, 99%, 0.5–10 lm) were supplied by Sigma Aldrich
(Steinheim, Germany). Sodium ﬂuorescein (100 mg/mL) was
obtained from Serb Laboratories (Paris, France). HMPAO kit was
purchased from Ceretec (Amersham, Arlington Heights, IL).
99mTc-pertechnetate was obtained from a molybdenum-99/tech-
netium-99m generator (Mallinckrodt, Petten, The Netherlands).
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-gly-
cero-3-phosphoethanolamine (NBD-PE) was purchased from
Invitrogen (Carlsbad, CA). Agarose MP was obtained from Roche
Applied Science (Mannheim, Germany).2.2. Liposome preparation
The FCL were prepared with the conventional thin-ﬁlm hydra-
tion technique as described previously [20] and consisted of DPPC,cholesterol and PEG2000-DSPE in a molar ratio of 1.85:1:0.15. The
lipid mixture (100 mM) was dissolved in ethanol (10 mL) and
evaporated to dryness by rotary evaporation under vacuum (Rota-
vapor R-210, BUCHI Laboratory Equipment, Zurich, Switzerland).
The resulting lipid ﬁlm was further dried under N2 to ensure that
all ethanol had evaporated. The lipid ﬁlm was hydrated with
10 mL ﬂuorescein (100 mg/mL). For control experiments, 99mTc-
HMPAO- and NBD-PE-containing liposomes were prepared using
the same technique. For the 99mTc-HMPAO-containing liposomes,
the lipid ﬁlm was hydrated with 10 mL glutathione (15.4 mg/
mL). NBD-PE was incorporated with the lipid bilayer to obtain a
liposome composition of DPPC, cholesterol, PEG2000-DSPE and
NBD-PE in a molar ratio of 1.85:1:0.15:0.03 (NBD-PE 1% of total li-
pid concentration) at 15 lmol/mL. The lipid ﬁlm was hydrated
with 10 mL HEPES-buffered saline (HBS, 20 mM HEPES and
135 mM NaCl, pH 7.4). The resulting lipid dispersions were sized
with sequential extrusion using a Lipex Extruder (Northern Lipids
Inc., Vancouver, Canada) and polycarbonate membrane ﬁlters
(Poretics Corporation, Livermore, CA) with a pore diameter of
600, 200, 100 nm and 50 nm to obtain liposomes with an average
diameter of around 100 nm.
2.3. Liposome characterization
The average hydrodynamic size and polydispersity index (PDI)
of the liposomes were determined with dynamic light scattering
(DLS) using a Malvern ALV CGS-3 system (Malvern Instruments
Ltd., Worcestershire, United Kingdom). The PDI value can range
from 0 for a monodisperse to 1 for a heterodisperse formulation.
Intensity correlation functions were measured using a wavelength
of 632.8 nm at a scattering angle of 90.
Non-encapsulated ﬂuorescein or glutathione was removed by
dialysis in HBS using Slide-A-Lyzer cassettes with a molecular
weight cut-off of 10 kDa (Pierce, Rockford, IL) during 48 h with four
times a change of buffer. Dye concentration of FCL was determined
by spectrophotometric measurement (UV Mini 1240, Shimadzu
Scientiﬁc Instruments, Columbia, USA, k = 490 nm) after lysis of
the liposomes using 2% Triton X-100 in HBS.
The total phospholipid concentration of the liposomes after
extrusion was determined with the phosphate assay as described
by Rouser et al. [22]. Preformed glutathione-containing liposomes
were labeled with 99mTc-HMPAO as described previously by Phil-
lips et al. [23]. Brieﬂy, 740 MBq 99mTcO4 was added to a lyophilized
HMPAO kit. Incubation of 0.5 mL liposomes with 1 mL 99mTcO4
HMPAO results in a concentration of 14.8 MBq/lmol lipid. Labeling
efﬁciency of 99mTc-HMPAO-containing liposomes was determined
in the liposome fraction after removal of the non-encapsulated
99mTc-HMPAO using a PD-10 desalting column (Amersham Biosci-
ences, Uppsala, Sweden) with HBS as eluent. The radioactivity of
the liposomes was measured with a VDC-404 dose calibrator
(Veenstra Instruments, Joure, The Netherlands). Differential scan-
ning calorimetry (DSC) measurements were performed in a capil-
lary cell microcalorimeter instrument (MicroCal VP-DSC,
Northampton, MA) to determine the phase transition melting tem-
perature (Tm) of the liposomes. The experiment was performed at
temperatures ranging from 20 to 70 C at a heating rate of
1 C min1 after an equilibration period of 15 min at 20 C.
2.4. Liposome stability
To investigate liposomal stability, the liposomes were stored at
4 C for 6 months. Afterwards, three samples of each liposome
batch were taken to measure size and PDI. Besides, the three
freshly prepared liposome compositions were heated to 60 C for
180 min to investigate the size distribution and PDI of the lipo-
somes after an extended heating period.
Fig. 1. Schematic representation of the FCL showing a PEG-coated lipid bilayer
surrounding an aqueous compartment containing ﬂuorescein.
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For quantitative dye release analysis, the FCL and NBD-PE-con-
taining control liposomes were exposed to different temperatures.
Therefore, agarose phantoms (0.5%) were prepared with deionized
water in 50 mL BD Falcon™ tubes. A small cavity was created with
a 100 lL pipette tip in the middle of the agarose phantom before
the onset of gelation. The remaining cavity after the tip was re-
moved was ﬁlled with liposomes containing a total dye concentra-
tion of 130 lM. The agarose phantoms were heated to 20, 37, 40,
43, 47 and 60 C for 30 s using a thermostat-controlled water bath.
To study the effect of room and body temperature, the agarose
phantoms were exposed to 20 and 37 C for an extended period
of 180 min. After heat exposure, the agarose phantoms were stored
at 4 C and dye release was measured with a Photon Imager (Bio-
space Lab, Paris, France) 24 h after heat exposure to allow the re-
leased dye to diffuse throughout the agarose phantoms.
Quantitative data (number of ﬂuorescent counts) were collected
and analyzed using M3Vision software (Biospace Lab, Paris,
France). FCL and NBD-PE-containing liposomes lysed with 2% Tri-
ton X-100 were used as positive control. Agarose phantoms
(0.5%) without liposomes were used as negative control.
2.6. Ex vivo liposome release studies
To determine the feasibility of FCL application in a clinical set-
ting, FCL (800 lM) were mixed with human blood (1 mL:1 mL) and
exposed to 20, 37 and 60 C for 30 s for visual detection of the re-
leased dye after heat-triggering. Photographs of the samples were
taken under normal light conditions and UV light (350 nm).
Additionally, 99mTc release from liposomes was investigated in
porcine muscle tissue using planar nuclear imaging with a dual-
head gamma camera (Vertex-MCD, ADAC, Milpitas, California) be-
fore and after heat exposure of the tissue. Two pieces of porcine
musculus semitendinosus were obtained from a pig that was pre-
viously used as a laboratory animal. The tissue was stored at 7 C
and used within 24 h after the pig was euthanized. The muscle tis-
sues were injected with 1 mL of 99mTc-HMPAO liposomes of which
one was heated to 60 C using hot air ﬂow and one was kept at
room temperature (20 C), as monitored by a locally placed ther-
mometer. Diffusion of 99mTc throughout the tissue was allowed
for 2 h at room temperature. The acquisition time was 90 s with
a count rate of approximately 10,000 cps. The images were
acquired in a 256  256 matrix with a pixel size of 2.32 mm 
2.32 mm and a 20% window centered around the 140 keV photo-
peak using a low energy collimator. Posterior and anterior images
were fused in one image.
2.7. MR-HIFU-triggered release study
Agarose phantoms were prepared in polypropylene beakers
with 0.5% agarose, 2% SiO2 and 800 mL deionized water. SiO2 is
added for a higher absorption coefﬁcient of the agarose gel, result-
ing in better absorption of the ultrasound beam. A small cavity was
created in the middle of the agarose phantom with a 2-mL pipette
tip, which was inserted in the middle of the agarose before the on-
set of gelation. After the agarose was cooled down, the pipette tip
was removed and the remaining cavity was ﬁlled with a mixture of
liposomes containing a dye concentration of 800 lM and agarose
gel, which was cooled down to 37 C to prevent premature release
from liposomes. After cooling down, more agarose gel (37 C) was
put on top until the cavity was completely covered to prevent scat-
tering of the ultrasound beam during MR-HIFU exposure.
The agarose phantoms containing FCL or the control NBD-PE-
containing liposomes were heated with the Philips Sonalleve 3T
MR-HIFU system (Philips Healthcare, Helsinki, Finland). This sys-tem was used to heat a volume of approximately 1.2  1.2 
5 cm3 using a 256-element phased-array ultrasound transducer
with volumetric heating capabilities and feedback control [24].
The ultrasound ﬁeld was continuous wave with a frequency of
1.2 MHz. Planning of the target area and temperature mapping
during treatment was performed by a 3T Philips Achieva MRI
scanner (Philips Healthcare, Best, The Netherlands). The tempera-
ture measurements were performed according to the Proton
Chemical Shift (PRF) method [25]. MR phase images of a gradient
echo sequence were used to calculate temperature maps. When
the spatial temperature in the ﬁeld-of-view of the ﬁrst acquired
phase image is known (e.g. in equilibrium at room temperature),
the temperature distribution in the second acquisition can be
considered as an absolute temperature map. The temperature
maps were used as input for the binary feedback loop of the HIFU
transducer. The binary feedback loop modulated in real-time the
transducer power resulting in a precise control of the temperature
in the ﬁeld-of-view. The MR gradient echo sequence is a dynamic
multi-slice sequence with the following parameters: TR/TE =
28/20 ms; ﬂip angle = 19; matrix = 160  99; ﬁeld-of-view =
400  250 mm; voxel size = 2.5  2.5  7 mm; acquisition time
per dynamic scan = 2.5 s. The MR slices were arranged as described
by Kohler et al. [26]. After a short preheating period (around
30–120 s), the desired temperature of 42 and 60 C was reached
and maintained for 30 s. The temperature accuracy was 0.1 C
based on the MR signal intensity [27].
After 24 h of storage at 4 C, the agarose phantoms were sliced
along the midsagittal plane. Dye release from the focal spot was
measured with the Photon Imager and analyzed using M3Vision
software as described previously. The total dye release after MR-
HIFU treatment was compared with FCL or NBD-PE-containing lip-
osomes lysed with 2% Triton X-100 were used as positive control.
Liposome-embedded agarose phantoms, which were not treated
with MR-HIFU, were used as negative control.
3. Results
3.1. Liposome preparation and characterization
FCL were prepared to determine their implementation as a
diagnostic tool in lesion demarcation after MR-HIFU-mediated
ablation (Fig. 1). Liposomes containing the lipophilic label NBD-
PE were prepared as control liposomes and 99mTc-HMPAO-contain-
ing liposomes were used for ex vivo studies (Table 1). Average
diameter of the liposomes was around 110 nm and the PDI was
Table 1
Liposome characteristics.
Liposome type Label Intraliposomal location Dye concentration
FCL Fluorescein Internal aqueous phase 7.1 mg/ml
NBD-PE NBD Lipid bilayer 131 lg/ml
99mTc-HMPAO 99mTc Internal aqueous phase 134 MBq/ml
Fig. 3. Percentage of ﬂuorescein release from liposomes after 30 s exposure to
different temperatures (mean ± SD, n = 3) (a). Fluorescence measurements in FCL-
containing phantoms exposed to different temperatures for 30 s (b). Fluorescence of
NBD-PE-containing liposomes in agarose phantoms after heat exposure to 37 and
60 C for 30 s (c).
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narrow size distribution. Storage of liposomes for 6 months at
4 C and heating of liposomes to 60 C for 180 min did not inﬂu-
ence the size distribution of the liposomes, indicating that the lip-
osomes are stable regarding changes in particle size distribution
(Fig. 2). DSC measurements conﬁrmed the Tm of the FCL to be at
42 C, which corresponds with the Tm of DPPC.
3.2. In vitro liposome release studies
The degree of dye release from FCL exposed to 20, 37, 40, 43, 47
and 60 C for 30 s is presented in Fig. 3a. Exposure to 43 C resulted
in 38% release, while 68% release was observed after exposure to
60 C. Exposure to 20 and 37 C, even after an extended exposure
period of 180 min, did not result in any detectable release. NBD-
PE-containing liposomes exposed to 37 and 60 C for 180 min did
not show detectable release of the ﬂuorescent label from lipo-
somes into the agarose phantoms (Fig. 3c), while NBD-PE liberated
using 2% Triton X-100 from the liposomal bilayer was able to dif-
fuse throughout the agarose gels. This indicates that the liposomal
formulation remains stable after heating. In order to exclude any
direct effects of temperature elevation on ﬂuorescence levels of
ﬂuorescein, an experiment was performed on ﬂuorescein solubi-
lized in demineralized water. The samples were heated for
15 min from 20 C up to 60 C, and emission spectra were mea-
sured. No detectable change in the emission spectra was observed
at different temperatures (data not shown), hence the increase in
ﬂuorescence can exclusively be ascribed to release from the FCL.
In Fig. 4, photographs from FCL in human blood exposed to dif-
ferent temperatures for 30 s, taken under normal light conditions
(Fig. 4a–c) and 350 nm UV light (Fig. 4d–f), are shown. No visual
differences between the samples were observed under normal
light conditions. However, under UV light conditions, ﬂuorescence
was clearly enhanced after exposure of the FCL to 60 C (Fig. 4f).
3.3. Ex vivo release studies
Distribution of ﬂuorescein throughout tissue cannot be visual-
ized directly in large tissue samples due to the insufﬁcient tissueFig. 2. Liposome size (nm) and PDI (mean ± SD, n = 3). Diameter of freshly prepared lipo
liposomes 6 months after storage at 4 C ( ). PDI ± SD is indicated by ( ).penetration depth. Therefore, ex vivo porcine muscle tissue was in-
jected with liposomes labeled with the water-soluble radioisotope
99mTc (99mTc-HMPAO-containing liposomes) to evaluate the re-
lease properties of the liposome formulation in tissue. Planar nu-
clear images of the tissue before and after heat exposure (60 C)
are shown in Fig. 5. Fig. 5b indicates the diffusion of 99mTc in tissue
after heat-triggering, which supports the feasibility of MR-HIFU-
triggered release from liposomes in tissue. In control tissue,
which was not exposed to heat, 99mTc did not show such enhanced
diffusion from the injection spot throughout the tissue (Fig. 5c
and d).somes ( ). Liposome diameter after 180 min of exposure to 60 C ( ). Diameter of
Fig. 4. Photographs from FCL dispersed in human blood. Samples are exposed to 20, 37 and 60 C for 30 s. Photographs taken under normal light conditions (a–c).
Photographs taken under 350 nm UV light emission (d–f). Exposure to 20 and 37 C (d and e). After exposure to 60 C, ﬂuorescence was clearly enhanced (f).
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The liposome spot inside the agarose phantoms was treated
with MR-HIFU, as is depicted in Fig. 6a. This region of interest
(ROI) was heated to 42 C (Tm of DPPC) and 60 C (ablation temper-
ature) for 30 s with MR-HIFU. In Fig. 6b and c, the heated liposome
spot in the agarose phantom is shown with MRI temperature map-
ping to demonstrate the accuracy of the MR-HIFU procedure. MR-
HIFU-induced heating to 42 C resulted in 28% release, whereas
68% release was observed after heating to 60 C. These results cor-
respond with the heat exposure results that were obtained with a
water bath (Fig. 3). MR-HIFU treatment of NBD-PE-containing lip-Fig. 5. Planar nuclear images of porcine muscle tissue injected with 99mTc-HMPAO-
containing liposomes. Distribution of 99mTc in the tissue before and after heat
exposure to 60 C (a and b). Diffusion of 99mTc throughout the tissue was observed
after heat-triggering. In control tissue, such enhanced distribution was not observed
(c and d).osomes did not lead to ﬂuorophore distribution throughout the
agarose phantoms, which is also in agreement with the in vitro
water bath results (see above).4. Discussion
This study was performed to obtain proof-of-concept for the
applicability of stable, long-circulating FCL as a tool for tumor
demarcation of non-palpable breast lesions after MR-HIFU-medi-
ated ablation. The liposomal size distribution of around 110 nm
enables passive tumor targeting facilitated by the EPR effect [17].
A 6-month storage period at 4 C showed that the FCL do not leak
their ﬂuorescent label and are stable regarding changes in particle
size distribution. A pharmaceutical acceptable shelf-life is impor-
tant for usage in a clinical setting and underlines the clinical appli-
cability of the FCL formulation.
Temperature-induced ﬂuorescein release from liposomes was
investigated by exposure of liposome-embedded agarose phan-
toms to different temperatures. Exposure of these phantoms to
20 and 37 C did not result in detectable release. Fluorescein re-
lease was limited at 40 C (about 10%) after short exposure times
(30 s) while it increased to 68% after 30 s exposure to 60 C
(Fig. 3), illustrating the sensitivity of the liposome formulation
for temperature changes above 37 C. No ﬂuorophore distribution
was observed after heating the NBD-PE-containing liposomes to
60 C, demonstrating the high stability of the liposome formula-
tion. Exposure of FCL dispersed in human blood to 20, 37 and
60 C for 30 s showed a clear enhancement of ﬂuorescence at
60 C compared to body temperature (37 C). The liposomal ﬂuo-
rescein concentration used in these experiments is sufﬁcient for
staining in a clinical setting. Due to self-quenching inside the lipo-
somes, ﬂuorescence is only observed when ﬂuorescein is released
from the liposomes. This attractive property contributes to efﬁ-
cient lesion demarcation since ﬂuorescence will only be detected
around the heated area, which excludes false positive staining of
healthy tissue.
Although animal-derived breast tissue or ex vivo human mam-
mary tissue may resemble breast tissue in a clinical setting, these
tissues, however, do not resemble tumor tissue itself with respect
to the tissue consistency. Tumor tissue is often characterized as
dense tissue, which is highly vascularized at the tumor periphery.
For this reason, muscle tissue was determined to be a suitable
alternative for tumor tissue in this setup for ex vivo diffusion
Fig. 6. Schematic drawing of the treatment planning positioned on the MR image of the agarose phantom during MR-HIFU treatment; the intended treatment cell is shown in
green (a). Transverse plane of the agarose phantom during the 42 C treatment, the temperature distribution can be deducted from the colour bar (b). Midsagittal plane of the
agarose phantom during 42 C treatment, indicating the heated area and reﬂecting the treatment cell as prepared during the treatment planning (c).
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experiments with porcine muscle tissue injected with 99mTc-
HMPAO showed enhanced distribution of 99mTc after heating to
60 C, indicating release and diffusion of 99mTc. This result addi-
tionally conﬁrms the potential applicability of the liposome formu-
lation for lesion demarcation in tissue.
To demonstrate the occurrence of temperature-induced release
after MR-HIFU-triggering, FCL-embedded agarose phantoms were
exposed to MR-HIFU ablation for 30 s. Short ablation temperatures
are critical when using MR-HIFU in the body. The short exposure
period is in accordance with clinically relevant MR-HIFU parame-
ters [24,26]. Long heating periods may cause peripheral absorption
of heat in non-targeted tissue, yielding the risk of unpredictable
thermal lesions [6]. Short exposure of FCL-embedded agarose
phantoms to MR-HIFU at 42 and 60 C resulted in dye release
kinetics in line with the in vitro results obtained with a water bath.
5. Conclusion
In conclusion, herein proof-of-concept for a novel approach for
lesion demarcation using the combination of long-circulating ﬂuo-
rescent liposomes and MR-HIFU-mediated ablation is presented.
FCL, which release their ﬂuorescent content after 30 s exposure
to MR-HIFU, which is in line with the clinically relevant MR-HIFU
treatment parameters, were successfully prepared. After release,
the treated ﬂuorescent lesion can be detected with UV light. This
method may offer a new tool for efﬁcient surgical resection of
non-palpable breast tumor lesions by enabling proper discrimina-
tion between tumor tissue and adjacent healthy tissue.
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